Fulcrum Therapeutics FULC
$ 3.2
7.58%
Quarterly report 2024-Q3
added 11-13-2024
Country |
USA |
IPO year |
2019 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Dr. Robert Gould |
Employees in the company |
73 |
Shares |
61.3 K |
Market Cap[1] |
$ 196 K |
EBITDA (LTM) |
$ -28.1 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.